Physician profile
Ryan Schipper
NPI 1356065932
$3,271.15
in general payments reported to CMS, 2019-2025
28 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $105 · 2023: $644 · 2024: $613 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,166.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $670.49 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $348.69 | 2023-2025 | |
| Bard Peripheral Vascular, INC. | $241.39 | 2025 | Trek |
| Abbvie INC. | $225.33 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $191.07 | 2024-2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $190.88 | 2024-2025 | Ojjaara, Blenrep |
| Incyte Corporation | $168.28 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Merck Sharp & Dohme LLC | $155.02 | 2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $153.94 | 2025 | Calquence, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $150.32 | 2023-2025 | Pomalyst, Opdivo |
| Celgene Corporation | $137.00 | 2022-2025 | Reblozyl |
| Daiichi Sankyo INC. | $100.32 | 2022-2025 | Injectafer, Enhertu |
| Geron Corporation | $71.75 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $60.07 | 2024-2025 | Monoferric |
| Janssen Biotech, INC. | $56.92 | 2022-2025 | Rybrevant |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $54.07 | 2023-2025 | Venclexta, Polivy |
| Beone Medicines USA, INC. | $44.96 | 2025 | Tevimbra |
| Sobi, INC | $32.26 | 2022-2023 | |
| Eisai INC. | $31.80 | 2025 | |
| Astellas Pharma US INC | $28.87 | 2025 | Xtandi |
| Pharmaessentia USA Corporation | $25.31 | 2024 | Besremi |
| Sumitomo Pharma America, INC. | $23.32 | 2025 | Orgovyx |
| Alnylam Pharmaceuticals INC. | $21.83 | 2023 | Givlaari |
| Sun Pharmaceutical Industries INC. | $19.84 | 2025 | |
| Blueprint Medicines Corporation | $18.95 | 2023 | Ayvakit |
| Syndax Pharmaceuticals, INC. | $16.63 | 2025 | |
| Novo Nordisk INC | $16.07 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Schipper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.